<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04099043</url>
  </required_header>
  <id_info>
    <org_study_id>PR-19-0032</org_study_id>
    <nct_id>NCT04099043</nct_id>
  </id_info>
  <brief_title>Cascade CGM 15-day Performance Assessment</brief_title>
  <acronym>CASPA</acronym>
  <official_title>Cascade Continuous Glucose Monitor 15-day Performance Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>WaveForm Technologies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>WaveForm Technologies Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To validate the feasibility of a 15-day wear period of the Cascade CGM system&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess a 15-day wear period for the Cascade CGM. This study includes ten subjects who will&#xD;
      interface with the system and take finger stick BGM glucose values for calibration. The wear&#xD;
      period includes four in-clinic days frequent blood draws and eleven at home days at a single&#xD;
      testing site.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2019</start_date>
  <completion_date type="Actual">October 13, 2019</completion_date>
  <primary_completion_date type="Actual">October 13, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>15-day Continuous Glucose Monitoring</measure>
    <time_frame>Fifteen days</time_frame>
    <description>Fifteen days of sensor wear with the Cascade CGM Smart Device App</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Continuous Glucose Monitoring</condition>
  <arm_group>
    <arm_group_label>Continuous Monitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Arm, Randomized</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cascade Continuous Glucose Monitoring System</intervention_name>
    <description>Continuous Glucose Monitoring for 15 days</description>
    <arm_group_label>Continuous Monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Signed informed consent form&#xD;
&#xD;
               -  Diagnosis of type 1 or type 2 (on insulin therapy) diabetes mellitus for at least&#xD;
                  6 months&#xD;
&#xD;
               -  18 years of age or older&#xD;
&#xD;
               -  Currently self-monitoring capillary blood glucose (on average at least three&#xD;
                  times per day or more) or on a CGM for at least three months&#xD;
&#xD;
               -  Willing to have blood glucose levels manipulated into high and low glucose levels&#xD;
                  during in clinic days if deemed appropriate per the protocol based on insulin&#xD;
                  use.&#xD;
&#xD;
               -  Willing to follow all study procedures, including attending all clinic visits&#xD;
                  during which a venous line will be inserted for blood sampling, wearing CGM&#xD;
                  sensors for entire study, performing fingertip glucose tests for self-monitoring&#xD;
                  and calibration, and keeping a diary of activities.&#xD;
&#xD;
               -  Be willing to wear two investigational CGM devices.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Known allergy to medical grade adhesives&#xD;
&#xD;
               -  Magnetic Resonance Imaging (MRI) scheduled during CGM sensor wear period&#xD;
&#xD;
               -  Persons with type 2 diabetes using diet and exercise only for diabetes management&#xD;
&#xD;
               -  Used an investigational drug within 30 days prior to study entry&#xD;
&#xD;
               -  Hematocrit &lt; 32% (obtained during screening)&#xD;
&#xD;
               -  Inadequate veins (in the opinion of the investigator) or known contraindication&#xD;
                  to placement of a dedicated peripheral line for venous blood withdrawal&#xD;
&#xD;
               -  Symptomatic coronary artery disease with a history of angina, or history of a&#xD;
                  myocardial infarction or coronary intervention (e.g., percutaneous transluminal&#xD;
                  coronary angioplasty [PTCA], stent placement), or coronary artery bypass graft&#xD;
                  (CABG) within the past six months&#xD;
&#xD;
               -  Diagnosis of the following diabetic autonomic neuropathies: orthostatic&#xD;
                  hypotension, heart rate anomalies, gastroparesis&#xD;
&#xD;
               -  Cerebrovascular incident within the past six month&#xD;
&#xD;
               -  History or presence of eczema, psoriasis, atopic or contact dermatitis&#xD;
&#xD;
               -  Subject is pregnant at the start of the study.&#xD;
&#xD;
               -  Current use or within one-week exposure to topical medications at the proposed&#xD;
                  insertion sites&#xD;
&#xD;
               -  Seizure disorder (epilepsy)&#xD;
&#xD;
               -  Malignancy within the past five years, except basal cell or squamous cell skin&#xD;
                  cancers&#xD;
&#xD;
               -  Major surgical operation within 30 days prior to screening&#xD;
&#xD;
               -  Other medical conditions that would pose safety concerns, interfere with study&#xD;
                  conduct or seriously compromise study integrity (reason for exclusion will be&#xD;
                  clearly documented by investigator or designee)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maja Navodnik Peložnik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Splošna bolnišnica Celje</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Splošna bolnišnica Celje</name>
      <address>
        <city>Celje</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

